Recently the Supreme Court of India rejected Novartis’s appeal for Glivec patent protection stating that an “incremental innovation” is not protected under Section 3 (d) of Indian Patent Act, 1970 (hereinafter “the Act”). This judgment has compelled the pharmaceutical companies to rethink their move towards research and development (R&D) and to obtain patents in India. Our patent regime does not encourage or support the patenting of incremental innovations
Register now for your free, tailored, daily legal newsfeed service.
Questions? Please contact firstname.lastname@example.orgRegister
Incremental pharmaceutical innovations: impact on public health & economy
To view this article you need a PDF viewer such as Adobe Reader.
Popular articles from this firm
If you would like to learn how Lexology can drive your content marketing strategy forward, please email email@example.com.
Related topic hubs
Senior Manager: Central Risk Unit
Customs Risk Management & Intelligence Division
"I use the newsfeeds to follow legislative changes and industry trends relevant to my division. I find the articles to be of a good quality and the topics are well researched and presented in a very user-friendly format."